GlassScriptPhysician profile
Padma Padival
NPI 1295478113
$2,750.64
in general payments reported to CMS, 2019-2025
28 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $770 · 2023: $1,069 · 2024: $781 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.87 | 2022-2024 | |
| Lilly USA, LLC | $259.63 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $255.86 | 2022-2024 | |
| Amgen INC. | $228.46 | 2022-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $168.30 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $164.89 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $133.55 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.61 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $114.93 | 2022-2023 | Verquvo |
| Glaxosmithkline, LLC. | $98.31 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $89.58 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $88.86 | 2023-2024 | Auvelity |
| Scpharmaceuticals INC. | $76.06 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.97 | 2022-2023 | |
| Lundbeck LLC | $62.65 | 2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $60.10 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $59.29 | 2022-2023 | Quviviq |
| Abbott Laboratories | $58.90 | 2022-2024 | Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.50 | 2025 | Lifevest |
| Biohaven Pharmaceutical Holding Company LTD. | $44.80 | 2022 | |
| Mylan Specialty L.P. | $29.60 | 2023 | Yupelri |
| Indivior INC. | $28.33 | 2023-2024 | Sublocade |
| Dexcom, INC. | $19.53 | 2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $19.28 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.40 | 2024 | Voquezna |
| Ardelyx, INC. | $14.26 | 2024 | Ibsrela |
| Astellas Pharma US INC | $13.58 | 2024 | Veozah |
| Eisai INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Padival listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.